Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aussie CSL Rejects Fear H1N1 Virus Could Mutate Before Vaccine Done

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL sought to discount concerns that an H1N1 vaccine against the latest influenza virus would mutate before people can receive shots. A spokeswoman said vaccinations are to begin in Australia in a few weeks, and it is "very unlikely" the virus would be able to mutate that soon. She said the kind of mutation required to make a virus ineffective would require at least a year in circulation. Australia has ordered 10 million doses of CSL's H1N1 vaccine and the company already is making test batches for clinical trials. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel